Seattle-based biopharmaceutical company Omeros Corp. (Nasdaq: OMER) named David Borges as the company's chief accounting officer in a Wednesday regulatory filing.
Borges joined Omeros in June 2020 and will take over the role at the end of this month. Prior to the promotion he has served as the company's associate vice president of financial planning and analysis. Borge is replacing Michael Jacobsen, who has worked at Omeros for 10 years but is retiring at the end of the month.
Borges will make $325,000 per year in his new role, and his target bonus for 2024 will be 35% of that, or $113,750. Jacobsen will stay on as a part-time employee and make $5,000 per month, and he will be eligible for a bonus.
Before joining Omeros, Borges spent five years as vice president of finance and administration at Bulletproof 360, a health and wellness company. Before that, he spent five years as chief financial officer at Advanced Refreshment, which Omeros called in the filing "a producer of private-label bottled water and water-based beverages." He also spent time at Merck & Co. and PwC earlier in his career.
Related coverage
Omeros was founded in 1994. The company is developing treatments aimed at cancer, addiction and compulsive disorders. Omeros is also developing a drug called Narsoplimab that is designed to prevent inflammation and damage to the membranes that line the heart and blood vessels.
In October, Omeros named Amgen and Procter & Gamble veteran Andreas Grauer as the company's chief medical officer. He is overseeing all clinical activities at Omeros in the role.
Omeros in April 2023 landed a $6.7 million grant over the course of three years from the federal National Institute on Drug Abuse for a drug candidate designed to treat cocaine addiction. In 2021, Omeros sold its Omidria franchise to the British eye care company Rayner Surgical Group Ltd. in a deal projected to be worth over $1 billion between the upfront payment, royalty payments and a commercial milestone payment. Omidria prevents excessive pupil constriction in cataract surgery.
For more stories like this one, sign up for Seattle Inno newsletters from the Puget Sound Business Journal and the American Inno network.
